论文部分内容阅读
目的探讨黛力新在慢性偏头痛治疗中的临床价值及慢性偏头痛的规范化治疗的重要性。方法选择符合慢性偏头痛入选标准的83例患者随机分为黛力新组(黛力新+规范化治疗药物组,n=42)和普通组(规范化治疗药物组,n=41),规范化治疗包括急性期对症止痛治疗以及缓解期以西比灵为代表的预防治疗,分别记录治疗前及治疗后第2、4、6、8周末患者每周头痛发作次数、每次发作持续时间及疼痛程度,同时记录不良反应情况。用SPSS 17.0统计软件进行统计分析,根据情况分别进行t检验、χ~2检验,P<0.05为差异有统计学意义。结果两组治疗前后比较治疗总有效率比较,差异均有统计学意义(P<0.05),黛力新组8周末头痛发作次数、每日发作时间减少较普通组更为显著,头痛程度显著减轻,有效率优于普通组,差异有统计学意义(P<0.05)。黛力新组出现头晕、口干、嗜睡等不良反应的发生率分别为7.1%,4.7%,2.4%,均可耐受,在用药1周内自行消失。结论规范化治疗慢性偏头痛是有效的,加用黛力新联合治疗可能具有更好的临床疗效,黛力新药物安全有效,其不良反应少见,且一般都能耐受。
Objective To investigate the clinical value of Deanxit in the treatment of chronic migraine and the importance of standardized treatment of chronic migraine. Methods Eighty-three patients eligible for chronic migraine were enrolled in this study. They were randomized to Deanxit (n = 42) and normotensive (n = 41), standardized treatment included Acute symptomatic and analgesic treatment and prophylaxis with xibinger as the representative of prevention and treatment were recorded before and after treatment 2,4,8,8 weeks of patients with weekly headache episodes per episode, duration of each episode and degree of pain, at the same time Record adverse reactions. SPSS 17.0 statistical software for statistical analysis, respectively, according to the situation t test, χ ~ 2 test, P <0.05 for the difference was statistically significant. Results The total effective rate of the two groups before and after treatment was statistically significant (P <0.05). The number of headache attacks and daily attack time were significantly more in the dexamethasone group at the end of the 8th week than those in the normal group, and the headache was significantly reduced , The effective rate is superior to the common group, the difference was statistically significant (P <0.05). The incidence of dizziness, dry mouth, drowsiness and other adverse reactions in the Deanxu group were 7.1%, 4.7% and 2.4% respectively, which could be tolerated and disappeared within one week after treatment. Conclusions The standardized treatment of chronic migraine is effective. Addition of Deanxit to the combination therapy may have better clinical efficacy. Deanxit is safe and effective, and its adverse reactions are rare and generally tolerated.